A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Trial Profile

A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Verteporfin (Primary)
  • Indications Choroidal neovascularisation; Degenerative myopia
  • Focus Registrational; Therapeutic Use
  • Acronyms Brilliance
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 17 Oct 2016 Status changed from recruiting to completed.
    • 12 Jan 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 12 Jan 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top